

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS X LLC,
Petitioner,

v.

ANACOR PHARMACEUTICALS, INC.,
Patent Owner.

Case No.: IPR2015-01776

Patent No.: 7,582,621

PETITIONER'S UPDATED EXHIBIT LIST

Appendix of Exhibits
Patent No. 7,582,621

EXHIBIT	DESCRIPTION	FILED
Ex. 1001	U.S. Patent No. 7,582,621 (“the ’621 Patent”)	<input checked="" type="checkbox"/>
Ex. 1002	Patent Cooperation Treaty Pub. No. WO 1995/033754 to Austin et al. (“ <i>Austin</i> ”)	<input checked="" type="checkbox"/>
Ex. 1003	U.S. Patent Pub. No. 2002/0165121 to Brehove (“ <i>Brehove</i> ”)	<input checked="" type="checkbox"/>
Ex. 1004	Patent Cooperation Treaty Pub. No. WO 2003/009689 A1 to Freeman et al. (“ <i>Freeman</i> ”)	<input checked="" type="checkbox"/>
Ex. 1005	U.S. Patent No. 6,042,845 to Sun et al. (“ <i>Sun</i> ”)	<input checked="" type="checkbox"/>
Ex. 1006	Declaration of Stephen Kahl, Ph.D. (“Kahl Decl.”)	<input checked="" type="checkbox"/>
Ex. 1007	Curriculum Vitae of Stephen B. Kahl, Ph.D.	<input checked="" type="checkbox"/>
Ex. 1008	Declaration of S. Narasimha Murthy, Ph.D. (“Murthy Decl.”)	<input checked="" type="checkbox"/>
Ex. 1009	Curriculum Vitae of S. Narasimha Murthy, Ph.D.	<input checked="" type="checkbox"/>
Ex. 1010	Prosecution History: U.S. Appl. No. 11/357,687 dated February 16, 2006	<input checked="" type="checkbox"/>
Ex. 1011	Prosecution History: Response To Restriction Requirement dated June 6, 2008	<input checked="" type="checkbox"/>
Ex. 1012	Prosecution History: Office Action dated August 26, 2008	<input checked="" type="checkbox"/>
Ex. 1013	Prosecution History: Reply to First Office Action dated January 23, 2009	<input checked="" type="checkbox"/>
Ex. 1014	Prosecution History: Notice of Allowance dated April 22, 2009	<input checked="" type="checkbox"/>
Ex. 1015	Prosecution History Of Continuation Application: Response to Office Action dated May 18, 2009	<input checked="" type="checkbox"/>
Ex. 1016	Prosecution History: Petition For Reconsideration Of Patent Term Adjustment Under 37 C.F.R. 1.705(d) dated September 25, 2009	<input checked="" type="checkbox"/>
Ex. 1017	Prosecution History: Grant of Petition For Reconsideration Of Patent Term Adjustment Under 37 C.F.R. 1.705(d) dated April 23, 2010	<input checked="" type="checkbox"/>
Ex. 1018	Prosecution History: Petition To Correct Inventorship Under 37 C.F.R. § 1.324 dated May 20, 2010	<input checked="" type="checkbox"/>
Ex. 1019	Prosecution History: Grant Of Petition To Correct Inventorship Under 37 C.F.R. § 1.324 dated July 16, 2013	<input checked="" type="checkbox"/>
Ex. 1020	U.S. Patent No. 2,831,866 to W.A. Freeman et al. (“the ’866 Patent”)	<input checked="" type="checkbox"/>

Appendix of Exhibits
 Patent No. 7,582,621

EXHIBIT	DESCRIPTION	FILED
Ex. 1021	U.S. Patent No. 3,093,659 to Bell et al. (“Bell”)	<input checked="" type="checkbox"/>
Ex. 1022	U.S. Patent No. 3,297,525 to Grier (“Grier”)	<input checked="" type="checkbox"/>
Ex. 1023	U.S. Patent No. 3,370,957 to Wagner et al (“Wagner”)	<input checked="" type="checkbox"/>
Ex. 1024	BioborJF® Specification Sheet (2015)	<input checked="" type="checkbox"/>
Ex. 1025	BioborJF® Material Safety Data Sheet (2004)	<input checked="" type="checkbox"/>
Ex. 1026	U.S. Patent No. 4,202,894 to Pfiffner (“Pfiffner”)	<input checked="" type="checkbox"/>
Ex. 1027	Michael P. Groziak, <i>Boron Therapeutics On The Horizon</i> , 8 AM. J. OF THERAPEUTICS 321-28 (2001) (“Groziak”)	<input checked="" type="checkbox"/>
Ex. 1028	Sudaxshina Murdan, <i>Drug Delivery to the Nail Following Topical Application</i> , 236 INT’L J. OF PHARM., 1-26 (2002) (“Murdan”)	<input checked="" type="checkbox"/>
Ex. 1029	U.S. Patent No. 4,822,822 to Arita et al. (“Arita”)	<input checked="" type="checkbox"/>
Ex. 1030	Declaration of Ryan J. Fletcher (“Fletcher Decl.”)	<input checked="" type="checkbox"/>
Ex. 1031	Kerydin® Prices, <i>available at</i> http://www.goodrx.com/kerydin	<input checked="" type="checkbox"/>
Ex. 1032	Q1 Medicare 2015 Kerydin® Price, <i>available at</i> http://www.q1medicare.com/PartD-2015MedicarePlan-RetailDrugPriceprint.php?stateReg=13MI&ndc=55724011121&formulary=00015191&contractId=H2322&planId=008&segmentId=0&zipCountyCode=26115&cplanType=M&cletter=K&cmode=state	<input checked="" type="checkbox"/>
Ex. 1033	Declaration of Brent E. Routman in Support of Petitioner’s Motion for Admission <i>Pro Hac Vice</i>	<input checked="" type="checkbox"/>
Ex. 1034	Declaration of Peter A. Gergely in Support of Petitioner’s Motion for Admission <i>Pro Hac Vice</i>	<input checked="" type="checkbox"/>
Ex. 1035	Declaration of Ryan J. Fletcher in Support of Petitioner’s Motion for Admission <i>Pro Hac Vice</i>	<input checked="" type="checkbox"/>
Ex. 1036	Supplemental Declaration of Ryan J. Fletcher	<input type="checkbox"/>
Ex. 1037	Biobor, R.E.D. Facts, EPA-738-R-93-004 (June 1993), http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=200009P5.PDF	<input type="checkbox"/>
Ex. 1038	Excerpts From The Certified Prosecution History For U.S. Patent No. 6,878,365, Including The MSDS Sheet For BioborJF®	<input type="checkbox"/>
Ex. 1039	Supplemental Declaration of Stephen Kahl, Ph.D.	<input type="checkbox"/>

Appendix of Exhibits
 Patent No. 7,582,621

EXHIBIT	DESCRIPTION	FILED
Ex. 1040	Supplemental Kerydin® Prices, <i>available at</i> http://www.goodrx.com/kerydin ; http://www.goodrx.com/how-goodrx-works ; http://www.goodrx.com/press	<input type="checkbox"/>
Ex. 1041	Q1 Medicare 2015 Kerydin® Price, <i>available at</i> https://q1medicare.com/PartD-2016MedicarePlan-RetailDrugPrice.php?ndc=10337090544&letter=K&formulary=00016286&stateReg=13MI&contractId=H2322&planId=008&segmentId=0#History ; https://q1medicare.com/PartD-About-Us-About-Us-About-Us-About-Us-About.php	<input type="checkbox"/>
Ex. 1042	Supplemental Declaration of S. Narasimha Murthy, Ph.D.	<input type="checkbox"/>
Ex. 1043	Declaration of Stephen Kahl, Ph.D., dated August 22, 2016	<input checked="" type="checkbox"/>
Ex. 1044	Declaration of S. Narasimha Murthy, Ph.D., dated August 23, 2016	<input checked="" type="checkbox"/>
Ex. 1045	Deposition Transcripts of Dr. Majella Lane dated July 7-8, 2016	<input checked="" type="checkbox"/>
Ex. 1046	Deposition Transcripts of Dr. Mahmoud A. Ghannoum dated July 18-19, 2016	<input checked="" type="checkbox"/>
Ex. 1047	Deposition Transcript of Dr. Howard Maibach dated July 13, 2016	<input checked="" type="checkbox"/>
Ex. 1048	Deposition Transcripts of Dr. Paul J. Reider dated July 21-22, 2016	<input checked="" type="checkbox"/>
Ex. 1049	12 <i>Progress in Heterocyclic Chemistry</i> , ch. 1, 1-21 (G.W. Gribble & T.L. Gilchrist eds., 1st ed., 2000) (Reider Dep. Ex. 5)	<input checked="" type="checkbox"/>
Ex. 1050	Ronald C. Wester <i>et al.</i> , <i>In Vivo Percutaneous Absorption of Boric Acid, Borax, and Disodium Octaborate Tetrahydrate in Humans Compared to in Vitro Absorption in Human Skin from Infinite and Finite Doses</i> , 45 <i>Toxicological Sci.</i> 42-51 (1998) (Maibach Dep. Ex. 9)	<input checked="" type="checkbox"/>
Ex. 1051	Press Release, Anacor, <i>Anacor Co-Founders Recognized for Scientific Achievements</i> (June 10, 2009), <i>available at</i> http://investor.anacor.com/releasedetail.cfm?releaseid=527603 .	<input checked="" type="checkbox"/>

Appendix of Exhibits
 Patent No. 7,582,621

EXHIBIT	DESCRIPTION	FILED
Ex. 1052	Patent Cooperation Treaty Pub. No. WO 2004/056322 A2 to Ving Lee and Stephen Benkovic (Reider Dep. Ex. 9)	<input checked="" type="checkbox"/>
Ex. 1053	U.S. Patent App. Pub. No. 2004/0259833 A1 to Benkovic <i>et al.</i>	<input checked="" type="checkbox"/>
Ex. 1054	Susan A. Hubbard, <i>Comparative Toxicology of Borates</i> , 66 Biological Trace Element Research, Proceedings of the Second Int'l Symposium on the Health Effect of Boron and Its Compounds 343-57 (Humana Press, 1998) (" <i>Hubbard</i> ")	<input checked="" type="checkbox"/>
Ex. 1055	U.S. Patent No. 7,465,836 to Lee <i>et al.</i> (" <i>Lee</i> ") (Reider Dep. Ex. 10)	<input checked="" type="checkbox"/>
Ex. 1056	Stephen J. Baker, <i>Therapeutic Potential of Boron-Containing Compounds</i> , 1 Future Med. Chem. (7) 1275-1288 (2009) (Reider Dep. Ex. 7)	<input checked="" type="checkbox"/>
Ex. 1057	Wenjie Li <i>et al.</i> , <i>An Improved Protocol for the preparation of 3-Pyridyl- and Some Arylboronic Acids</i> , 67 J. Org. Chem. 5394-97 (2002)	<input checked="" type="checkbox"/>
Ex. 1058	Donald E. Garrett, <i>Borates Handbook of Deposits, Processing, Properties, and Use</i> , 333-429 (Academic Press, 1998)	<input checked="" type="checkbox"/>
Ex. 1059	Stephen J. Baker <i>et al.</i> , <i>Boron-Containing Inhibitors of Synthetases</i> , 40 Chem. Soc. Rev. 4279-85 (2011) (Reider Dep. Ex. 8)	<input checked="" type="checkbox"/>
Ex. 1060	Wenqian Yang <i>et al.</i> , <i>Boronic Acid Compounds as Potential Pharmaceutical Agents</i> , 23 Med. Research Rev., No. 3, 346-68 (2003)	<input checked="" type="checkbox"/>
Ex. 1061	Ronald C. Wester <i>et al.</i> , <i>In Vivo Percutaneous Absorption of Boron as Boric Acid, Borax, and Disodium Octaborate Tetrahydrate in Humans: A Summary</i> , 66 Biological Trace Element Research, Proceedings of the Second Int'l Symposium on the Health Effect of Boron and Its Compounds 101-09 (Humana Press, 1998)	<input checked="" type="checkbox"/>
Ex. 1062	Patent Cooperation Treaty Pub. No. WO 2005/013892 A3 to Lee <i>et al.</i>	<input checked="" type="checkbox"/>
Ex. 1063	Patent Cooperation Treaty Pub. No. WO 2007/095638 A3 to Baker <i>et al.</i>	<input checked="" type="checkbox"/>
Ex. 1064	Certified U.S. Provisional App. No. 60/654,060 (" <i>the '060 Provisional</i> ")	<input checked="" type="checkbox"/>

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.